Back to today’s briefing

Story perspectives

Novartis Strikes $5.2B Deal for Cardiovascular Drug Development

9/4/2025

22 5

Summary

Story summary

Novartis and China's Argo Biopharmaceutical have entered a $5.2 billion licensing agreement for cardiovascular drugs using siRNA technology.
The deal includes an upfront payment of $160 million and potential milestone payments.
Novartis plans to license two candidates targeting severe hypertriglyceridemia and mixed dyslipidemia.
Cardiovascular diseases resulted in 20.5 million deaths globally in 2021.

1 of 1

Story summary

Novartis and China's Argo Biopharmaceutical have entered a $5.2 billion licensing agreement for cardiovascular drugs using siRNA technology.
The deal includes an upfront payment of $160 million and potential milestone payments.
Novartis plans to license two candidates targeting severe hypertriglyceridemia and mixed dyslipidemia.
Cardiovascular diseases resulted in 20.5 million deaths globally in 2021.